0Y3M Stock Chart & Stats
$8.38
-$0.28(-3.36%)
At close: 4:00 PM EDT
$8.38
-$0.28(-3.36%)
Day’s Range― - ―
52-Week Range$7.89 - $11.67
Previous CloseN/A
Volume6.00
Average Volume (3M)1.23K
Market Cap
$466.14M
Enterprise Value$229.30
Total Cash (Recent Filing)$288.19M
Total Debt (Recent Filing)$6.99M
Price to Earnings (P/E)―
Beta0.38
Next Earnings
Oct 29, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.83
Shares Outstanding51,336,975
10 Day Avg. Volume724
30 Day Avg. Volume1,232
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.83
Price to Sales (P/S)53.08
P/FCF Ratio-3.14
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$26.33Price Target Upside214.24% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)0.13
Revenue Forecast (FY)$83.99M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetA very low debt-to-equity ratio and modest absolute debt provide durable financial flexibility for a clinical-stage biotech. This cushion supports continued R&D and partnership funding gaps, reducing near-term refinance risk and giving management time to advance programs without immediate creditor pressure.
Significant Partnership Milestone PotentialMaterial potential milestone payments from multiple partners create a meaningful, non-dilutive financing pathway if clinical goals are met. Over 2–6 months this structural upside can convert into funded development or reimbursements, aligning incentives with partners and de-risking program financing.
Proprietary CYTOPE Platform With External ValidationOwnership of a validated platform that attracts partners is a lasting competitive advantage. CYTOPE’s ability to generate collaborations and licensing interest improves deal flow, supports pipeline breadth, and increases chances of milestone-triggered revenue and external R&D funding over multiple programs.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow erodes runway absent milestone receipts or financing. For a development-stage biotech this necessitates periodic capital raises or reliance on partner payments, increasing dilution risk and constraining ability to independently finance multiple late-stage programs.
Declining Revenue And Deep LossesFalling revenue alongside very large negative margins reflects reliance on lumpy collaboration income and heavy R&D spend. This weak earnings profile reduces internal resilience, delays path to sustainable profitability, and raises the probability that future operations will depend on external funding or milestone timing.
Revenue Volatility From Collaboration-dependent ModelA business model dependent on upfront, milestone and royalty timing produces lumpy receipts and makes cash planning difficult. Structural revenue volatility increases funding uncertainty, complicates long-term budgeting for trials, and magnifies execution risk tied to partner program outcomes.
Prothena News
0Y3M FAQ
What was Prothena’s price range in the past 12 months?
Prothena lowest share price was $7.89 and its highest was $11.67 in the past 12 months.
What is Prothena’s market cap?
Prothena’s market cap is $466.14M.
When is Prothena’s upcoming earnings report date?
Prothena’s upcoming earnings report date is Oct 29, 2026 which is in 75 days.
How were Prothena’s earnings last quarter?
Prothena released its earnings results on Aug 06, 2026. The company reported -$0.36 earnings per share for the quarter, beating the consensus estimate of -$0.39 by $0.03.
Is Prothena overvalued?
According to Wall Street analysts Prothena’s price is currently Undervalued.
Does Prothena pay dividends?
Prothena does not currently pay dividends.
What is Prothena’s EPS estimate?
Prothena’s EPS estimate is -0.21.
How many shares outstanding does Prothena have?
Prothena has 51,336,975 shares outstanding.
What happened to Prothena’s price movement after its last earnings report?
Prothena reported an EPS of -$0.36 in its last earnings report, beating expectations of -$0.39. Following the earnings report the stock price went up 4.922%.
Which hedge fund is a major shareholder of Prothena?
Currently, no hedge funds are holding shares in GB:0Y3M
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prothena Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$26.33 (214.24% Upside)
$26.33 (214.24% Upside)
Insider Transactions
Bought Shares
Worth $3.4M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-33.05%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-24.18%
Trailing 12-Months
Company Description
Prothena
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
0Y3M Stock 12 Month Forecast
Average Price Target
$26.33
▲(214.24% Upside)
Technical Analysis
Lexicon Pharmaceuticals
―
―
Zevra Therapeutics
―
Corvus Pharmaceuticals
―
Alumis Inc.
―